Editorial: the burden of chronic liver disease – an ecological method sees the wood for the trees

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 5, 2016, Pages 531-532

  Madden, R ^a   Mallet, V ^b,c,d  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; CHRONIC LIVER DISEASE; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; ENVIRONMENTAL FACTOR; HEALTH CARE SYSTEM; HEPATITIS B; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 84982829072     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13698     Document Type: Editorial

References (10)

1. Gye H, Greenhill S. Revealed: David Bowie died from liver cancer and was told it was terminal a year ago, 2016. Available at: http://www.dailymail.co.uk/news/article-3395326/David-Bowie-died-liver-cancer-told-terminal-year-ago.html (accessed May 19 2016).
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
3. von Wulffen M, Clark PJ, Macdonald GA, et al. Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. Aliment Pharmacol Ther 2016; 44: 68–77.
4. Schwarzinger M, Thiebaut S, Mallet V, Rehm J. The counfounding role of severe comorbidities and alcohol use disorders on prognosis in chronic hepatitis C virus infection: an analysis of the 2008-2012 French national hospital discharge database. J Hepatol 2015; 62: S237.
5. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–33.
6. Wiese M, Fischer J, Loebermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 2014; 59: 49–57.
7. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162: 407–19.
8. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584–93.
9. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015; 62: 355–64.
10. Piroth L, Pol S, Miailhes P, et al. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int 2015; 35: 1950–8.